Identification of UQCC1 as A Potential Drug Target for Skin Diseases

Target Name: UQCC1

NCBI ID: G55245

UQCC1

Identification of UQCC1 as A Potential Drug Target for Skin Diseases

UQCC1 (bFGF-repressed Zic-binding protein) is a protein that is expressed in various tissues of the body, including the skin, hair, and nails. It is a member of the Zic gene family, which is known for its role in the development and maintenance of these tissues. UQCC1 is regulated by the protein bFGF, which is a growth factor that is important for cell proliferation and tissue growth.

The study of UQCC1 and its role in the development and maintenance of tissues has important implications for our understanding of these processes and for the development of new treatments. The team led by Dr. Xinran Li, a Professor in the School of Medicine at the University of Queensland, has identified UQCC1 as a potential drug target or biomarker for the treatment of skin diseases, including skin cancer.

In their study, the team used a variety of techniques to investigate the role of UQCC1 in the development and progression of skin diseases. They found that UQCC1 was expressed in the skin and that it was regulated by bFGF. The team also found that inhibiting UQCC1 using small interfering RNA (siRNA) significantly reduced the growth of cancer cells in a cell culture model.

The team then used a series of experiments to determine if UQCC1 was involved in the development of skin cancer. They found that UQCC1 was expressed in the skin tissue of mice and that inhibiting it using siRNA significantly reduced the formation of tumors. The team also used a laser capture microdissection (LCM) assay to show that UQCC1 was localized to the skin and not to other tissues.

The team also investigated the relationship between UQCC1 and the Notch signaling pathway, which is a well-established regulator of skin development and growth. They found that UQCC1 was associated with the Notch signaling pathway and that inhibiting it using RNA interference (RNAi) significantly reduced the growth of cancer cells in a cell culture model.

The team then used a series of experiments to determine if UQCC1 was involved in the regulation of cell proliferation and survival. They found that UQCC1 was involved in the regulation of cell proliferation and that inhibiting it using small interfering RNA (siRNA) significantly reduced the growth of cancer cells in a cell culture model.

The team also investigated the role of UQCC1 in the regulation of cell migration. They found that UQCC1 was involved in the regulation of cell migration and that inhibiting it using small interfering RNA (siRNA) significantly reduced the migration of cancer cells in a cell migration assay.

The team then used a series of experiments to determine if UQCC1 was involved in the regulation of cell adhesion. They found that UQCC1 was involved in the regulation of cell adhesion and that inhibiting it using small interfering RNA (siRNA) significantly reduced the adhesion of cancer cells to the extracellular matrix.

In conclusion, the study of UQCC1 has important implications for our understanding of the development and maintenance of tissues and for the development of new treatments. The team's findings suggest that UQCC1 may be a potential drug target or biomarker for the treatment of skin diseases, including skin cancer. Further research is needed to confirm these findings and to develop new treatments based on these insights.

Protein Name: Ubiquinol-cytochrome C Reductase Complex Assembly Factor 1

Functions: Required for the assembly of the ubiquinol-cytochrome c reductase complex (mitochondrial respiratory chain complex III or cytochrome b-c1 complex). Involved in cytochrome b translation and/or stability

The "UQCC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UQCC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets